Study Suggests Link Between Type 2 Diabetes and Low Melatonin

Published Online: Friday, May 17, 2013
Follow Pharmacy_Times:
Women with low levels of melatonin may be at a higher risk for developing type 2 diabetes, according to a recent study published in the April 3, 2013, issue of the Journal of the American Medical Association.

The study included 370 women from the U.S. Nurses’ Health Study who developed type 2 diabetes from 2000 to 2012 and 370 non-diabetic controls. Melatonin levels were measured through urine and blood samples before the development of diabetes. When analyzing the relationship between melatonin and diabetes development, the researchers evaluated other risk factors such as demographics, eating habits, and sleep patterns.

Women with the lowest levels of melatonin were 2.17 times more likely to develop type 2 diabetes than women with the highest melatonin levels.

“While there is a correlation between melatonin and insulin resistance, we cannot tell from this study if low melatonin is the cause,” said Dr. Joel Zonszein, director of the clinical diabetes center at Montefiore Medical Center in New York City, in a press release. “We are far away from melatonin as a treatment.”

The authors conclude that more research is needed to determine if low melatonin levels are a risk factor for type 2 diabetes in the general population.


Related Articles
The FDA has approved the intravitreal implant, Iluvien 0.19 mg, as the first long-term treatment for diabetic macular edema.
Pharmacists who participate in community-based diabetes care teams play a pivotal role in reducing A1C levels among patients with poorly controlled diabetes.
The dexamethasone intravitreal implant, Ozurdex, is now indicated to treat all patients with diabetic macular edema.
The FDA has cleared the Nova StatStrip Glucose Hospital Meter System to become the first blood glucose monitoring system for use in critically ill patients who have been hospitalized.
Latest Issues
$auto_registration$